Tag: TRUS biopsy

Combining multiparametric MRI with genomic testing is revolutionizing prostate cancer detection and treatment. By leveraging the strengths of both technologies, doctors can achieve more accurate diagnoses, guide personalized treatment decisions, and improve patient outcomes. Learn how these tools are shaping the future of prostate cancer care. keep reading

What if the biopsy you were told was MRI-guided wasn't really MRI-guided at all? Fusion technology merges an earlier MRI scan with real-time ultrasound, and the handoff is imperfect. New research adds a fresh concern: as prostate volume grows, detection of clinically significant cancer drops, no matter how carefully the target was chosen. keep reading

As many as 75% of PSA tests come back falsely positive, and for years that single number sent men straight to a needle biopsy with all its risks. Today, noninvasive biomarker tests in blood and urine, paired with mpMRI, are reshaping who truly needs the procedure and who can safely be spared the discomfort and the worry. keep reading

Less than a third of men with a PSA result in the "gray zone" of 4–10 actually have prostate cancer. Yet for years, that number alone sent patients straight to biopsy. Today, mpMRI offers a smarter first step and a newly FDA-approved blood test called IsoPSA may be the safety net for cases MRI can't fully resolve. keep reading

MRI-based diagnosis offers a more accurate and less invasive path for prostate cancer detection than traditional methods. By identifying clinically significant tumors before biopsy, the MRI pathway helps prevent overtreatment while safeguarding quality of life. keep reading

Overtreatment of low-risk prostate cancer can leave men with lasting side effects from unnecessary whole-gland treatment. Today, advances like multiparametric MRI, active surveillance, and focal therapy are offering safer, smarter alternatives that protect health and preserve quality of life. keep reading

New tools like biomarker tests and 3T mpMRI are transforming how doctors evaluate a high PSA. Learn how these innovations reduce unnecessary prostate biopsies—saving patients from risk, stress, and costs—while delivering greater clarity in prostate cancer diagnosis. keep reading

In the world of prostate cancer (PCa), there is a dangerous cell pattern called cribriform (pronounced crib’ ri-form) or simply Cr. It has a distinctive appearance that looks similar to a sieve or a plate with lots of holes. Cr is associated with aggressive Gleason grade 4 cancer. Also, there is another PCa type called keep reading

“Out of all the stars labeled Box Office Poison by the Independent Theater Owners Association in 1938, Katharine Hepburn is one who maintains a high degree of name recognition today…” This is the opening sentence of a January 2023 article in Hollywood Revue, explaining how the Great Kate was dealt a blow to her reputation—a keep reading

Does PSA screening reduce PCa mortality, or doesn’t it? We know that PSA is not specific for cancer, since many prostate conditions can cause a rise in PSA blood levels. We also know that an elevated PSA can lead to a conventional TRUS-guided biopsy, and that such biopsies can either miss prostate cancer or... keep reading